Telomir Pharmaceuticals (TELO) Other Operating Expenses (2023 - 2024)

Telomir Pharmaceuticals (TELO) posted Other Operating Expenses of $370500.0 for Q1 2024, up 81.81% sequentially from $203784.0 in Q4 2023.

Telomir Pharmaceuticals (TELO) Other Operating Expenses (2023 - 2024) Analysis & Trends

Telomir Pharmaceuticals has reported Other Operating Expenses for 2 years, with the latest figure at $370500.0 in Q1 2024.

Quarterly Other Operating Expenses changed N/A year-over-year to $370500.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $370500.0 (down 67.33% YoY) and the FY2024 annual result came in at $370500.0, down 76.47% from the prior year.
Other Operating Expenses improved to $370500.0 in Q1 2024 per TELO's latest filing, from $203784.0 in the prior quarter.
Over five years, Other Operating Expenses peaked at $667626.0 in Q2 2023 and troughed at $203784.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Telomir Pharmaceuticals	69.05 Mn	69.05 Mn	-

Download Data